Wall Street Signals: JZZ Technologies, Inc. Acquisition of Company with Five Therapeutics

JZZ Technologies, Inc. Acquisition of Company with Five Therapeutics

 

Working with respected bioscience companies JZZ Technologies, Inc. intends to advance five novel therapeutics utilizing natural compounds for age-related healthcare issues.

As announced via press release on November 16, 2021, JZZ Technologies, Inc. (OTC Pink: JZZI) signed an LOI with NutraEdge Bioscience Corp. dated November 10, 2021. This press release supplements the release of November 16, 2021. JZZ Technologies, Inc. intends to continue its due diligence on the target acquisition, a US Biotechnology Company that has a range of natural healthcare formulations assigned to it, which are largely unknown in the USA, and that demonstrate bioactivity and antimicrobial activity.

Under the terms of the Letter of Intent, dated November 10, 2021, JZZ Technologies, Inc. will acquire 100% ownership of NutraEdge Biosciences Corp., 5% of GenBio Inc., and 25% of Nutrific.

Research into these formulations has focused on Cytokine Inhibition (Pulmonary), Cytokine inhibition -(Cardiovascular), Protein/cell blocking or reverse tryptase, Antibacterial inhibition selected pathogens, and Anti-Inflammatory responses to viruses

The new venture will only collaborate with highly specific, specialized manufacturing companies with a clear understanding of cellular extraction delivery in water-soluble plant compound profiles.

Charles Cardona, CEO of JZZ Technologies, Inc., stated, "When making an acquisition, I like to follow the successful blueprint that has been used by Warren Buffet for decades, which is to acquire companies and keep successful management intact. A great way to value any prospective acquisition according to the "Orator of Omaha" is to look for a company whose management is passionate about the business."

Cardona went on to say, "That is exactly what we have here -a successful team already in place that is passionate about the work they do. JZZ Technologies looks to maintain that and enhance it so that it can reach its fullest potential."

About GenBio Inc.

Based in Southern California, GenBio is an early-stage biotechnology company researching novel therapeutics from a variety of extracts. Based on recent US research, the company has created an Investigational New Drug (IND) research program from novel natural compounds that are highly effective as anti-inflammatory agents. Chief Science Officer, Professor Lindsay Brown is a renowned international researcher leading GenBio's product development and research. The company also has access to other global scientific teams that are investigating specific properties for the same new, disruptive molecular platforms for pain relief, anti-inflammation, and age-related healthcare issues.

About JZZ Technologies, Inc.

JZZ Technologies, Inc. is a diversified technology company engaged in the following two distinct business sectors: (i) it's digital media business which includes online media and apps (activelifestylemedia.com), content creation, digital marketing, streaming video content, publishing, and free over-the-air television (EyeOnTV) targeted to active adults 55+, and; (ii) strategic biotechnology and bioscience-related to Human Life Extension and Human Longevity that can be immediately leveraged to support improved quality of life for the senior population.

Contact:
JZZ Technologies, Inc.
Charles Cardona, CEO